Phase 3 N=10 Chronic Versus Acute Dosing of Sodium Citrate for Swimming 200m
Alkalosis
Primary: Time — 144.2; 145.3; 145.3; 144.8 seconds
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=224 B. Lactis HN019 for Functional Constipation
Constipation
Primary: Whole Gut Transit Time
Phase 3 N=499 Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism
Secondary Hypogonadism
Primary: Change From Baseline in Total Morning Testosterone at 26 Weeks — 280.9; 214.7 ng/dL
Phase 3 N=183 A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Infection, Human Immunodeficiency Virus
Primary: Mean Change From Baseline in Plasma HIV-1 RNA at Day 8 — -1.432 log10 copies/milliliter (mL) — p=<0.001
Phase 3 N=1,116 Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Crohn's Disease
Primary: Induction Phase: Percentage of Participants Achieving Clinical Remission at Week 6 — 6.8; 14.5 percentage of participants — p=0.0206
Phase 3 N=416 Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Crohn's Disease
Primary: Percentage of Participants in Clinical Remission in the Tumor Necrosis Factor Alpha (TNFα) Antagonist Failure Subpopulation — 12.1; 15.2 percentage of participants…
Phase 3 N=383 SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Binge Eating Disorder
Primary: Change From Baseline in the Number of Binge Days Per Week at Visit 8 (Weeks 11-12) — -2.51; -3.87 Binge days per week — p=<0.001
Phase 3 N=72 Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients
Epilepsy
Primary: Number of Subjects With Reported Adverse Events (AE) — 3; 3; 11; 10 participants
Phase 3 N=895 Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis
Ulcerative Colitis
Primary: Induction Phase: Percentage of Participants With a Clinical Response at Week 6 — 25.5; 47.1 percentage of participants — p=< 0.0001
Phase 3 N=196 Safety and Effectiveness of Omega 3-Fatty Acids, EPA Versus DHA, for the Treatment of Major Depression
Major Depressive Disorder
Primary: Score on a Depression Severity Rating Scale Over Eight Weeks — -10.34; -9.26; -9.49 units on a scale
Phase 3 N=105 S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia
Leukemia
Primary: 3-year Disease-free Survival (DFS) Rate — 96; 100 percentage of patients
Phase 3 N=556 A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment
Rheumatoid Arthritis
Primary: Percentage of Participants With Disease Activity Score 28 Joints (DAS28) Remission at Week 24 — 40.4; 34.8 Percentage of participants — p=0.2055
Phase 3 N=304 Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children
Partial Epilepsy in Children and Adolescents
Primary: Change From Baseline in Seizure Frequency — 62.0; 36.6 seizures/month — p=0.2490
Phase 3 N=362 Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight
Candidiasis
Primary: Death or Candidiasis — 31; 37 participants
Phase 3 N=566 A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine
Diabetes Mellitus, Type 2
Primary: Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 26 — -0.82; -0.66 Percentage of HbA1c in the blood — p=<0.0001